DEVON, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of data being presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting. The meeting is being held In Bethesda, MD on March 2nd through March 5th, 2020.
Related Posts
Invest In Weed TV
News Highlights
- Silly Mistakes to Avoid When Purchasing Cannabis Equipment July 17, 2020
- Stages of the Cannabis Plant Growth Cycle December 3, 2019
- Future Farm Prepares Maine-Grown Hemp Biomass and Seeds for Processing and Market November 25, 2019
- Auxly Announces Outdoor Cultivation Expansion Through the Launch of Robinsons Outdoor Grow November 18, 2019
- Aleafia Health Outdoor Harvest Yields 10,300 kg of Dried Flower at $0.08 Cost per Gram November 11, 2019
- Future Farm’s Maine Hemp Harvest Nearing Completion October 31, 2019
- Massive Revenues Expected as Hemp, Inc. Updates Shareholders on the First Phase of Processing its Hemp Harvest in Oregon October 25, 2019
- KALY – Kali-Extracts Publishes Photos From Historic First Legal Hemp Harvest October 18, 2019
Leave a Reply